You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.
Treatment Research Initiative to Cure ALS meeting 2022

Treatment Research Initiative to Cure ALS

Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.

Initiation of efficacy studies inamyotrophic lateral sclerosis

Iniation of efficacy studies on MS and ALS

Nevrargenics launches efficacy studies on MS and ALS models through Experimentica and Charles River respectively.

CEO interview beyond biotech podcast

Interview of our CEO on Beyond Biotech podcast

CEO Andy Whiting gives an interview to Liza Laws, Senior Editor of Labiotech about neurodegeneration and Nevrargenics's drugs.

Kings College collaboration Parkinson's

Collaboration with King’s College in Parkinson’s

Research collaboration launch with Professor Susan Duty at King’s College, looking the application of our drugs in Parkinson’s disease models.

Mandale Park, Durham

Nevrargenics own premises

Nevrargenics acquires its own premises for the development of its offices and laboratories on Mandale Park in Durham.

Safety studies neuroscience CNS

Lead drug candidate safety studies of completed

Two (once weekly and twice weekly dosing), 28 day tox studies were completed on NVG0645 showing a potential therapeutic window.

neuroprotection in a model of Parkinson’s disease

Nevrargenics drug candidate provides neuroprotection in Parkinson’s model

Nevrargenics reports that lead drug candidate provides neuroprotection in a 6-hydroxydopamine model of Parkinson’s disease.

Neuro-restorative and protective effects of drug NVG0645

Neuro-restorative and protective effects of drug NVG0645 presented

Nevrargenics reports multi-neuro-restorative and protective effects using lead drug as a new therapeutic strategy for ALS.